Enliven Therapeutics (ELVN) Liabilities and Shareholders Equity (2019 - 2026)

Enliven Therapeutics has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $464.9 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $464.9 million, up 53.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 53.54% YoY), and the FY2025 annual result was $476.2 million, up 46.17% from the prior year.
• Liabilities and Shareholders Equity came in at $464.9 million for Q1 2026 at Enliven Therapeutics, down from $476.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $503.9 million in Q2 2025 to a low of $59.1 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $302.9 million (2023), against an average of $292.1 million.
• Across the five-year window, Liabilities and Shareholders Equity slumped 44.78% in 2022 and soared 363.66% in 2023, its largest moves.
• Enliven Therapeutics' Liabilities and Shareholders Equity stood at $83.3 million in 2022, then soared by 226.38% to $271.9 million in 2023, then advanced by 19.82% to $325.8 million in 2024, then jumped by 46.17% to $476.2 million in 2025, then slipped by 2.38% to $464.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $464.9 million (Q1 2026), $476.2 million (Q4 2025), and $490.9 million (Q3 2025), per Business Quant data.